Forty Seven Inc. Announces Publication in The New England Journal of Medicine of 5F9 Phase 1b Clinical Data in Non-Hodgkin’s ...
Publication Reaffirms Therapeutic Potential of CD47 Inhibition as Novel Approach to Treating Cancer Enrollment Ongoing in Phase 2 Portion of Clinical Trial Evaluating 5F9 in Combination with Rituximab for Patients with Relapsed/Refractory NHL MENLO PARK, …